Investor Relations

The Ambu share has a track record of high performance. And growth is a strong parameter for our success.

Latest news

18

May. 2019

Cook Medical and Ambu announce collaboration to address endoscope-related infections (no. 11)

Cook Medical and Ambu A/S have agreed on terms to enter into a partnership under which Cook will distribute Ambu’s single-use, disposable duodenoscope in the U.S., following FDA clearance. The scope is currently being developed by Ambu to help address infections caused by cross-contamination*. Since 2015, U.S. regulatory authorities have increased their focus on endoscope cross-contamination, particularly reusable endoscopes for gastrointestinal use.

The use of reusable endoscopes can pose a contamination risk to patients because the devices are difficult to reprocess between uses. Alternatively, single-use scopes could have a significant impact on device-related infections and improve hospital workflows because they do not require cleaning or repair.

Our mission is to improve patient care and we were looking for a solution to reduce the risk of infections associated with the use of reusable endoscopes,” said Barry Slowey, Vice President of Cook Medical’s Endoscopy business. “Our collaboration with Ambu is based on a shared goal to enhance patient safety.

"This is a significant milestone towards our vision of a single-use ERCP solution,” said Juan Jose Gonzalez, CEO of Ambu. “Together with Cook Medical we plan to bring single-use endoscopes to patients undergoing ERCP procedures, to reduce the risk of serious cross-contaminations."

No further details about the agreement will be disclosed at this time, but the agreement is not expected to have any impact on the outlook for Ambu concerning growth, earnings or free cash flows towards September 2020 as put forth in connection to the earnings relase for H1 on May 1 2019.

*Ambu is currently pursuing regulatory clearance from the U.S. FDA for its single-use duodenoscope. These products are currently not available for sale in the U.S. Expected release for sale is before end of September 2020.

Download
You can download this company announcement: Cook Medical and Ambu announce collaboration to address endoscope-related infections.

13

May. 2019

Conference call today - Regarding appointment of new CEO

Ambu will be hosting a conference call with Chairman of the Board Jens Bager and CFO Michael Højgaard in line with the announcement from Friday May 10, 2019 regarding the appointment of new CEO.

The call will take place today Monday May 13 2019 at 3 pm (CET).

At the call, Jens Bager will give a short introduction and explain the background for the decision after which participants will have the opportunity to ask questions directly to the Chairman and the CFO.

In order to participate, please call five minutes before the start on one of the telephone numbers below and enter the following access code: 70957005#.

  • Denmark Toll: +45 3544 5577
  • United Kingdom Toll: +44 33 3300 0804
  • United States Toll: +1 631 913 1422

To listen to the conference call either live or after the call, please go to this site: www.ambu.com/webcastnewCEO

Download
You can download this press relase (pdf).

10

May. 2019

Ambu appoints new CEO (no. 10)

Ambu’s board of directors has appointed Juan-José Gonzalez as the new CEO, effective May 15, 2019, to replace Lars Marcher who resigns from his position.

Jens Bager, Chairman of the Ambu Board of Directors, comments, “During Lars Marchers' leadership, Ambu has developed a strong and broad platform of medtech products, which have formed the basis for impressive growth. I and the rest of the board would like to thank Lars very much for his contribution to this remarkable decade in Ambu’s history. At the same time, I am pleased to have secured Juan-José Gonzalez, whom I am confident will be an excellent successor and the right choice to lead Ambu into its next growth phase.

Juan-José Gonzalez is an engineer and MBA graduate and has held a number of senior positions in the US healthcare group Johnson & Johnson for the past 12 years. Most recently, he has been President for the activities of the subsidiary DePuy Synthes in the US, with a turnover of DKK 33bn and more than 5,000 employees. DePuy Synthes is one of the world's leading manufacturers of orthopedic and neurosurgical products. Prior to joining Johnson & Johnson in 2007, Juan-José Gonzalez was a commercial director of the pharmaceutical company Pfizer, responsible for Europe, Africa and the Middle East, and for five years employed by the global consulting firm McKinsey & Company. Juan-José Gonzalez is 46 years old, an American citizen and relocates from the United States to Denmark with his wife and their two children.

"Ambu is facing a major international breakthrough with a number of high-tech products in the business area of Visualization with a broad program of single-use endoscopes in the USA and the rest of the world. With Juan-José Gonzalez as CEO, we ensure that Ambu also has the necessary global experience to execute the announced strategy and ensure the succesful commercialization of our product launches,” says Jens Bager.

Juan-José Gonzalez looks forward to joining Ambu as the new CEO. “The strength of Ambu is the company’s ability to deliver on differentiated innovation. Its pioneering of single-use endoscopy is a great example of Ambu’s focus on innovation. I am deeply committed to the plan to continue Ambu’s legacy of bringing innovative products to patients around the world. With Ambu’s recent launches, strong pipeline and committed people, I am very confident about our future." says Juan-José Gonzalez.

Financial expectations
The replacement of the CEO does not change the announced financial expectations for 2018/19 – except for the one-off costs listed below – or the financial targets for 2020 as outlined in the Big Five strategy. Planned product launches up to the end of the financial year 2019/20 and Ambu´s program for the upcomming DDW congress in San Diego on 18-21 May 2019 is thus unaffected by this.

In relation to Lars Marcher's resignation, there will be one-off costs of approx. DKK 38m, which for accounting purposes will be recognized in the income statement as Special items. The costs relates, among other things, to salary during the period of notice and the costs of the remaining value of already granted share options calculated according to the Black Scholes formula. These Black Scholes costs amounts to DKK 16m which so far has been distributed over the allocation period of the share options, but will now be fully charged to the income statement in the 3rd quarter of the financial year 2018/19 as a direct consequence of Lars Marcher's resignation. 

Before special items as referred above the financial expectations for the financial year 2018/19 are unchanged compared to the guidance provided in the interim report for our 2nd quarter on May 1, 2019, and can hereafter be summarized as:

  • Organic growth of approx. 15-16%.
  • EBIT margin before special items of approx. 22-24%.
  • Free cash flow of approx. DKK 400-475m.

Contact
For further information please contact:
Jens Bager, Chairman of the Board, tel. +45 2299 0304 
Michael Højgaard, CFO, tel. +45 4030 4349 

Press Inquiries: Morten Huse Eikrem-Jeppesen, PressConnect, tel. +45 5385 0770

Download
You can download this company announcement: Ambu appoints new CEO (pdf).

Annual General Meeting 2018
(Generalforsamling 2018)

The AGM was held on 12 December in Copenhagen. See full video transmission

Go to Annual General Meeting

Financial Reports

Get the latest annual & quarterly reports
Read more

Annual Key Figures

Get an overview of Ambu's key figures
Read more

Presentations

Get the latest investor presentations and webcasts
Read more

Strategy

Learn more about Ambu's present strategy
Read more

Upcoming events

13

May. 2019

Conference call - Regarding appointment of new CEO

Conference call with Chairman of the Board Jens Bager and CFO Michael Højgaard regarding the appointment of new CEO.

The call will take place today Monday May 13 2019 at 3 pm (CET).

At the call, Jens Bager will give a short introduction and explain the background for the decision after which participants will have the opportunity to ask questions directly to the Chairman and the CFO.

In order to participate, please call five minutes before the start on one of the telephone numbers below and enter the following access code: 70957005#.

  • Denmark Toll: +45 3544 5577 
  • United Kingdom Toll: +44 33 3300 0804 
  • United States Toll: +1 631 913 1422

To listen to the conference call either live or after the call, please go to this site: www.ambu.com/webcastnewCEO
 

04

Jun. 2019

Handelsbanken Q2 roadshow

Stockholm
4 June 2019

26

Jun. 2019

Danske Bank Q2 roadshow

Edinburgh
26 June 2019

News from Ambu

Sign up and receive news and company announcements from Ambu

Sign up

 

keyboard_arrow_up